CEO Keith Grossman details how `Pain Company’ Nevro is grabbing a big piece of a competitive market episode artwork

EPISODE · Nov 11, 2022 · 49 MIN

CEO Keith Grossman details how `Pain Company’ Nevro is grabbing a big piece of a competitive market

from DeviceTalks Podcast Network · host DeviceTalks Podcast Network

In this episode, we’ll talk with Keith Grossman, who brought his long, successful track record as a medtech CEO to what he sees as a truly disruptive neurostimulation company. We’ll talk with Grossman about his decision to join medtech even though unlike some of his counterparts he enjoyed organic chemistry (aka, the Medtech career creator) in college. Over his career, Grossman helped create new medical device marks by leading companies such as Thoratec and Conceptus toward sizable acquisitions. At Nevro, Grossman says he’s overseeing the company’s transformation into a pain company, one that’s managed to grab 20% of a competitive market very quickly. Thanks to Pulse Technologies for sponsoring this episode. Thank you for listening to the DeviceTalks Weekly Podcast. Subscribe to this podcast on any major podcast application.

Episode metadata supplied by the publisher feed · Published Nov 11, 2022

Embed this episode

Ready to play

CEO Keith Grossman details how `Pain Company’ Nevro is grabbing a big piece of a competitive market

0:00 49:41

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of DeviceTalks Podcast Network?

This episode is 49 minutes long.

When was this DeviceTalks Podcast Network episode published?

This episode was published on November 11, 2022.

Can I download this DeviceTalks Podcast Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!